tiprankstipranks
Xvivo Perfusion AB (XVIPF)
OTHER OTC:XVIPF

Xvivo Perfusion AB (XVIPF) Stock Price & Analysis

4 Followers

XVIPF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$19.50 - $34.65
Previous Close$26.83
Volume1.00
Average Volume (3M)203.00
Market Cap
$854.57M
Enterprise Value$863.85M
Total Cash (Recent Filing)kr197.95M
Total Debt (Recent Filing)kr292.99M
Price to Earnings (P/E)96.4
Beta1.35
Apr 24, 2024
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding31,499,470
10 Day Avg. Volume30
30 Day Avg. Volume203
Standard Deviation0.18
R-Squared0.00838
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%5.95%0.83%93.22%
0.00%
Insiders
0.83% Other Institutional Investors
93.22% Public Companies and
Individual Investors

XVIPF FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was $19.50 and its highest was $34.65 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Currently, no data Available
    When is Xvivo Perfusion AB’s upcoming earnings report date?
    Xvivo Perfusion AB’s upcoming earnings report date is Apr 24, 2024 which is in 27 days.
      How were Xvivo Perfusion AB’s earnings last quarter?
      Xvivo Perfusion AB released its earnings results on Jan 25, 2024. The company reported $0.215 earnings per share for the quarter, beating the consensus estimate of $0.046 by $0.169.
        Is Xvivo Perfusion AB overvalued?
        According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Xvivo Perfusion AB pay dividends?
          Xvivo Perfusion AB does not currently pay dividends.
          What is Xvivo Perfusion AB’s EPS estimate?
          Xvivo Perfusion AB’s EPS estimate is $0.04.
            How many shares outstanding does Xvivo Perfusion AB have?
            Xvivo Perfusion AB has 31,499,470 shares outstanding.
              What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
              Xvivo Perfusion AB reported an EPS of $0.215 in its last earnings report, beating expectations of $0.046. Following the earnings report the stock price went down -11.774%.
                Which hedge fund is a major shareholder of Xvivo Perfusion AB?
                Currently, no hedge funds are holding shares in XVIPF
                ---

                Xvivo Perfusion AB Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                24.79%
                12-Months-Change

                Fundamentals

                Return on Equity
                5.23%
                Trailing 12-Months
                Asset Growth
                30.12%
                Trailing 12-Months

                Company Description

                Xvivo Perfusion AB

                Xvivo Perfusion AB is a medical technology company which develops and markets innovative system solutions for the preservation and evaluation of donated organs outside the body awaiting transplantation. The company supply transplantation clinics worldwide with advanced technological products for the preservation and evaluation of lungs.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Haemonetics
                Thermo Fisher
                Waters
                Abbott Labs

                Best Analysts Covering XVIPF

                1 Year
                Jakob LembkeSEB Enskilda
                Not Ranked
                1 Year Success Rate
                0/0 ratings generated profit
                0%
                1 Year Average Return
                0.00%
                initiated a buy rating 9 months ago
                Copying Jakob Lembke's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis